[go: up one dir, main page]

FR23C1035I2 - Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson - Google Patents

Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson

Info

Publication number
FR23C1035I2
FR23C1035I2 FR23C1035C FR23C1035C FR23C1035I2 FR 23C1035 I2 FR23C1035 I2 FR 23C1035I2 FR 23C1035 C FR23C1035 C FR 23C1035C FR 23C1035 C FR23C1035 C FR 23C1035C FR 23C1035 I2 FR23C1035 I2 FR 23C1035I2
Authority
FR
France
Prior art keywords
carbidopa
dopa
prodrugs
disease
treating parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1035C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1035(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of FR23C1035I1 publication Critical patent/FR23C1035I1/fr
Application granted granted Critical
Publication of FR23C1035I2 publication Critical patent/FR23C1035I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR23C1035C 2014-10-21 2023-09-29 Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson Active FR23C1035I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (fr) 2014-10-21 2015-10-21 Promédicaments de carbidopa et de l-dopa et leur utilisation pour traiter la maladie de parkinson

Publications (2)

Publication Number Publication Date
FR23C1035I1 FR23C1035I1 (fr) 2023-12-08
FR23C1035I2 true FR23C1035I2 (fr) 2025-04-18

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1035C Active FR23C1035I2 (fr) 2014-10-21 2023-09-29 Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson

Country Status (37)

Country Link
US (7) US9446059B2 (fr)
EP (3) EP4186510A1 (fr)
JP (6) JP6567049B2 (fr)
KR (3) KR20240113982A (fr)
CN (4) CN111454290B (fr)
AR (1) AR102389A1 (fr)
AU (4) AU2015335941B2 (fr)
BR (1) BR112017008198B1 (fr)
CA (1) CA2965379A1 (fr)
CY (2) CY1121826T1 (fr)
DK (1) DK3209302T3 (fr)
ES (1) ES2739536T3 (fr)
FI (1) FIC20230014I1 (fr)
FR (1) FR23C1035I2 (fr)
HR (1) HRP20191285T1 (fr)
HU (2) HUE044115T2 (fr)
IL (3) IL251829B (fr)
LT (2) LT3209302T (fr)
LU (1) LUC00304I2 (fr)
MX (2) MX381069B (fr)
MY (1) MY189519A (fr)
NL (1) NL301224I2 (fr)
NO (1) NO2023013I1 (fr)
PH (1) PH12017500746B1 (fr)
PL (1) PL3209302T3 (fr)
PT (1) PT3209302T (fr)
RS (1) RS58972B1 (fr)
RU (2) RU2021103000A (fr)
SA (1) SA521421115B1 (fr)
SG (1) SG11201703170RA (fr)
SI (1) SI3209302T1 (fr)
SM (1) SMT201900376T1 (fr)
TR (1) TR201908296T4 (fr)
TW (2) TWI718999B (fr)
UA (1) UA120437C2 (fr)
WO (1) WO2016065019A1 (fr)
ZA (1) ZA201702760B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299128A3 (fr) 2014-03-13 2024-04-17 Neuroderm Ltd. Compositions d'inhibiteurs de dopa-décarboxylase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX381069B (es) * 2014-10-21 2025-03-12 Abbvie Inc Profármacos de carbidopa y l-dopa y métodos de uso.
EP4295909A3 (fr) * 2016-04-20 2024-07-17 AbbVie Inc. Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
CA3028423A1 (fr) 2016-06-22 2017-12-28 Medchem Partners, Llc. Donneurs d'oxyde nitrique
WO2018154447A1 (fr) * 2017-02-21 2018-08-30 Neuroderm Ltd Compositions d'inhibiteurs de dopa-décarboxylase
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (fr) 2017-11-16 2019-05-23 Orion Corporation Nouvelle utilisation et nouvelles formes posologiques pharmaceutiques
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
MY203233A (en) 2018-09-13 2024-06-19 Univ Canberra Methods of inhibition
SG11202104499RA (en) * 2018-11-15 2021-05-28 Abbvie Inc Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (fr) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Compositions pharmaceutiques comprenant des dérivés d'amide de lévodopa et leurs utilisations
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
EP3972970A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments à base de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
EP3972959A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
EP3972971A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
WO2020234277A1 (fr) 2019-05-21 2020-11-26 H. Lundbeck A/S Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4223288B1 (fr) 2022-02-07 2024-03-06 Berlirem GmbH Nouveau kit de préparations pharmaceutiques pour le traitement de la maladie de parkinson
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) * 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
CN1671724A (zh) 2002-06-20 2005-09-21 日本水产株式会社 前药、其作为医药的应用及其制法
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004069146A2 (fr) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'amide l-dopa et utilisations de ceux-ci
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
JP5160786B2 (ja) 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US20050163841A1 (en) 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
EP1751087B1 (fr) * 2004-06-04 2012-06-27 XenoPort, Inc. Derives de levodopa, et compositions et utilisations associees
US7718633B2 (en) 2004-07-06 2010-05-18 Abbott Laboratories Prodrugs of HIV protease inhibitors
CN101365439B (zh) * 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
EP2063865A1 (fr) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Administration intestinale pendant 24 heures à long terme de lévodopa/carbidopa
EP2037964A2 (fr) * 2006-06-16 2009-03-25 Solvay Pharmaceuticals B.V. Preparation combinees contenant du bifeprunox et un agoniste de la dopamine
EP2125702A1 (fr) 2006-12-21 2009-12-02 Xenoport, Inc. Promédicaments diesters diméthyle substitués à base de levodopa et procédés d'utilisation
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
US8193243B2 (en) 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
EP2515876B1 (fr) 2009-11-09 2016-01-06 XenoPort, Inc. Compositions pharmaceutiques et formes galéniques orales d'un promédicament de lévodopa et procédés d'utilisation
WO2011109767A2 (fr) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Inhibiteurs de la gélatinase et promédicaments
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
CA2823642A1 (fr) 2010-12-10 2012-06-14 Synagile Corporation Compositions de promedicament de levodopa perfusable par voie sous-cutanee
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
WO2014141261A1 (fr) 2013-03-13 2014-09-18 Neuroderm Ltd Procédé pour le traitement de la maladie de parkinson
JP2016516018A (ja) 2013-03-15 2016-06-02 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
MX381069B (es) 2014-10-21 2025-03-12 Abbvie Inc Profármacos de carbidopa y l-dopa y métodos de uso.
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP4295909A3 (fr) 2016-04-20 2024-07-17 AbbVie Inc. Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
WO2018059739A1 (fr) 2016-09-29 2018-04-05 Berlirem Gmbh Dérivés de l-dopa pour le traitement de maladies neurologiques
WO2018154447A1 (fr) 2017-02-21 2018-08-30 Neuroderm Ltd Compositions d'inhibiteurs de dopa-décarboxylase

Also Published As

Publication number Publication date
PT3209302T (pt) 2019-07-19
CN107206013A (zh) 2017-09-26
ES2739536T3 (es) 2020-01-31
NL301224I1 (fr) 2023-03-29
WO2016065019A1 (fr) 2016-04-28
JP7688087B2 (ja) 2025-06-03
SG11201703170RA (en) 2017-05-30
TWI755257B (zh) 2022-02-11
US20180079762A1 (en) 2018-03-22
UA120437C2 (uk) 2019-12-10
LUC00304I2 (fr) 2025-09-22
CY2023010I2 (el) 2023-06-09
US10174061B2 (en) 2019-01-08
SA521421115B1 (ar) 2022-03-01
JP2019218356A (ja) 2019-12-26
EP3209302A1 (fr) 2017-08-30
IL268885B (en) 2020-08-31
AU2025238004A1 (en) 2025-10-16
JP2023174770A (ja) 2023-12-08
HUE044115T2 (hu) 2019-10-28
PH12017500746A1 (en) 2017-10-30
CN111362980B (zh) 2022-10-18
EP3569587A1 (fr) 2019-11-20
US11091507B2 (en) 2021-08-17
US20190375770A1 (en) 2019-12-12
NZ730996A (en) 2024-04-26
US20160106765A1 (en) 2016-04-21
KR20170071599A (ko) 2017-06-23
FR23C1035I1 (fr) 2023-12-08
CA2965379A1 (fr) 2016-04-28
DK3209302T3 (da) 2019-05-13
CN111454290B (zh) 2022-12-23
US10730895B2 (en) 2020-08-04
US20220153765A1 (en) 2022-05-19
RU2021103000A (ru) 2021-03-01
PL3209302T3 (pl) 2019-10-31
IL251829A0 (en) 2017-06-29
JP6750076B2 (ja) 2020-09-02
US20230106081A1 (en) 2023-04-06
AU2023210650A1 (en) 2023-08-24
NZ769153A (en) 2024-04-26
ZA201702760B (en) 2022-05-25
HRP20191285T1 (hr) 2019-10-18
US20160362431A1 (en) 2016-12-15
AU2021201414B2 (en) 2023-05-11
AU2015335941B2 (en) 2021-04-01
CY2023010I1 (el) 2023-06-09
RU2017117413A3 (fr) 2019-05-30
RS58972B1 (sr) 2019-08-30
JP6567049B2 (ja) 2019-08-28
CY1121826T1 (el) 2020-07-31
JP2025118978A (ja) 2025-08-13
MX393568B (es) 2025-03-24
BR112017008198A2 (pt) 2017-12-26
AU2015335941A1 (en) 2017-05-04
TR201908296T4 (tr) 2019-06-21
AU2021201414A1 (en) 2021-03-25
MX2021003840A (es) 2022-06-30
KR102537018B1 (ko) 2023-05-30
TWI718999B (zh) 2021-02-21
CN111494395A (zh) 2020-08-07
PH12017500746B1 (en) 2021-12-15
JP2021183628A (ja) 2021-12-02
CN111362980A (zh) 2020-07-03
CN111494395B (zh) 2024-06-21
MX2017005236A (es) 2017-07-26
NL301224I2 (nl) 2023-08-16
US20200262852A1 (en) 2020-08-20
LTC3209302I2 (fr) 2025-10-10
CN111454290A (zh) 2020-07-28
EP3209302B1 (fr) 2019-04-24
AR102389A1 (es) 2017-02-22
BR112017008198B1 (pt) 2021-02-09
SMT201900376T1 (it) 2019-09-09
MX381069B (es) 2025-03-12
IL251829B (en) 2019-09-26
LT3209302T (lt) 2019-06-10
TW201630924A (zh) 2016-09-01
IL268885A (en) 2019-10-31
JP2020189864A (ja) 2020-11-26
IL276493A (en) 2020-09-30
RU2017117413A (ru) 2018-11-26
RU2743347C2 (ru) 2021-02-17
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
HUS2300009I1 (hu) 2023-03-28
JP2017537066A (ja) 2017-12-14
NO2023013I1 (no) 2023-03-20
US9446059B2 (en) 2016-09-20
MY189519A (en) 2022-02-16
EP4186510A1 (fr) 2023-05-31
LTPA2023519I1 (fr) 2023-06-26
FIC20230014I1 (fi) 2023-03-31
TW202131931A (zh) 2021-09-01
KR20240113982A (ko) 2024-07-23
SI3209302T1 (sl) 2019-06-28

Similar Documents

Publication Publication Date Title
FR23C1035I2 (fr) Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
HUE051476T2 (hu) Kannabidiolsav alkalmazása az epilepszia kezelésében
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
EP3307754A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles de la peau
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
EP3376977A4 (fr) Récupération et traitement d'embryons humains formésin vivo
HUE059387T2 (hu) Parkinson-kór kezelése
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
PT3373922T (pt) Composições e métodos para usar no tratamento de homocistinúria
FR3030270B1 (fr) Procede de traitement cosmetique et kit associe
PL3727349T3 (pl) Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego
MD3364975T2 (ro) Combinație de trazodonă și gabapentină pentru tratamentul durerii
EP3344239A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
EP3322481A4 (fr) Traitement d'affections de la coiffe des rotateurs
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
EP2981324A4 (fr) Méthodes et articles manufacturés pour le traitement de la peau
EP2825184A4 (fr) Compositions et méthodes pour le traitement de la douleur
EP3426803A4 (fr) Compositions et méthodes de traitement de la maladie de parkinson
GB201504144D0 (en) Treatment of Parkinson's disease